Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.
Davidson
R N
RN
St Mary's Hospital Medical School, Dept of Infectious and Tropical Diseases, Lister Unit, Northwick Park Hospital, Harrow, UK.
Di Martino
L
L
Gradoni
L
L
Giacchino
R
R
Russo
R
R
Gaeta
G B
GB
Pempinello
R
R
Scott
S
S
Raimondi
F
F
Cascio
A
A
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D002648:Child; D002675:Child, Preschool; D004337:Drug Carriers; D005260:Female; D006678:HIV / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D016867:Immunocompromised Host; D007223:Infant; D018314:Leishmania infantum; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000276:immunology; D008081:Liposomes; D008297:Male; D008875:Middle Aged
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B